Erik has 25+ years of leadership experience in corporate development and finance in the biopharma industry. He has completed numerous financings and a wide variety of sell-side and buy-side transactions, including mergers & acquisitions, out-licensing, in-licensing, co-development, spinout, arbitration, and manufacturing, for companies including ALZA, Johnson & Johnson, Catalyst Biosciences, Anacor Pharmaceuticals, and Coherus. Erik began his career on Wall Street in investment banking and equity research. He received two degrees at the University of Pennsylvania, a B.S. in economics from the Wharton School, with concentrations in finance and accounting, and a B.A.S. in computer science engineering.
